Pelthos Therapeutics Inc. (PTHS) — SEC Filings

Latest SEC filings for Pelthos Therapeutics Inc. (PTHS), explained in plain English.

Sentiment Overview: 1 bearish, 47 neutral, 2 mixed

Recent Filings (50)

• Pelthos Director Malamut Files Ownership Change — 4 · 2026-04-06T17:03:21-04:00 [neutral] Risk: low
  Richard Malamut, a Director at Pelthos Therapeutics Inc. (PTHS), reported a transaction on April 2, 2026, related to a Rule 10b5-1(c) trading plan. The filing i
• Pelthos Therapeutics Inc. Insider Trading Update — 4 · 2026-04-06T17:03:04-04:00 [neutral] Risk: medium
  On April 2, 2026, Ezra M. Friedberg reported a change in beneficial ownership of securities for Pelthos Therapeutics Inc. The filing details transactions relate
• 4 Filing — 4 · 2026-04-06T17:02:43-04:00 [neutral]
• Pelthos Therapeutics Inc. Reports Ownership Change — 4 · 2026-04-06T17:01:00-04:00 [neutral] Risk: medium
  On April 2, 2026, Peter Greenleaf, a reporting person associated with Pelthos Therapeutics Inc., reported a change in beneficial ownership of securities. The fi
• Pelthos Therapeutics Files Amended Ownership Report — 4/A · 2026-04-01T17:45:39-04:00 [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an amended Form 4/A on April 1, 2026, to report changes in beneficial ownership of securities. The filing pertains to the period
• 4/A Filing — 4/A · 2026-04-01T17:45:20-04:00 [neutral]
• 4/A Filing — 4/A · 2026-04-01T17:44:43-04:00 [neutral]
• Pelthos Therapeutics Files Amended Ownership Report — 4/A · 2026-04-01T17:44:11-04:00 [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an amended Form 4/A on April 1, 2026, to report changes in beneficial ownership of securities. The filing pertains to the period
• Pelthos Therapeutics Files Amended Ownership Report — 4/A · 2026-04-01T17:43:41-04:00 [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an amended Form 4/A on April 1, 2026, to report changes in beneficial ownership of securities. The filing pertains to a period o
• 4/A Filing — 4/A · 2026-04-01T17:42:47-04:00 [neutral]
• Pelthos Therapeutics Files 4/A Amendment — 4/A · 2026-04-01T17:39:34-04:00 [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an amendment (4/A) on April 1, 2026, to a statement of changes in beneficial ownership of securities. The filing pertains to a r
• Pelthos Therapeutics Inc. Files 8-K on Executive Changes — 8-K · 2025-12-23T00:00:00.000Z [neutral] Risk: medium
  Pelthos Therapeutics Inc. filed an 8-K on December 23, 2025, reporting on the departure of directors or certain officers, the election of directors, the appoint
• Pelthos Therapeutics Files 8-K on Shareholder Votes — 8-K · 2025-12-17T00:00:00.000Z [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on December 17, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Ch
• Pelthos Seeks Shareholder Nod for Key Financing, Board Elections — DEF 14A · 2025-11-25T00:00:00.000Z [mixed] Risk: medium
  Pelthos Therapeutics Inc. (PTHS) is holding its Annual Meeting on December 17, 2025, to address critical governance and financing matters. Shareholders will vot
• Pelthos Swings to $21.7M Loss Post-Merger, ZELSUVMI Drives Revenue — 10-Q · 2025-11-13T00:00:00.000Z [mixed] Risk: high
  Pelthos Therapeutics Inc. (PTHS) reported a significant operational shift and financial performance for the nine months ended September 30, 2025, following its
• Pelthos Therapeutics Files 8-K: Material Agreement, Debt, Equity Sales — 8-K · 2025-11-07T00:00:00.000Z [neutral] Risk: medium
  Pelthos Therapeutics Inc. announced on November 7, 2025, that it entered into a material definitive agreement. The company also reported the creation of a direc
• Pelthos Therapeutics Files 8-K for Reg FD Disclosure — 8-K · 2025-10-14T00:00:00.000Z [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on October 14, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or mate
• Pelthos Therapeutics Files Amended Financials Post-Merger — 8-K/A · 2025-09-16T00:00:00.000Z [neutral] Risk: medium
  Pelthos Therapeutics Inc. filed an 8-K/A on September 16, 2025, to amend a previous filing. This amendment includes unaudited condensed financial statements for
• Pelthos Therapeutics Files 8-K for Reg FD Disclosure — 8-K · 2025-09-03T00:00:00.000Z [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on September 3, 2025, reporting an event on September 2, 2025. The filing is primarily for Regulation FD Disclosure and i
• Pelthos Therapeutics Files 8-K on Financials — 8-K · 2025-08-18T00:00:00.000Z [neutral] Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on August 18, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
• Pelthos' Losses Mount Amid Cash Crunch, Going Concern Doubts — 10-Q · 2025-08-13T00:00:00.000Z [bearish] Risk: high
  Pelthos Therapeutics Inc. (PTHS) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $5.4 million, up from $4.3 million
• Pelthos Therapeutics Reports Material Agreements & Equity Sales — 8-K · 2025-07-02T00:00:00.000Z [neutral] Risk: medium
  Pelthos Therapeutics Inc. filed an 8-K on July 2, 2025, reporting several material events. These include entering into a definitive agreement, the completion of
• Channel Therapeutics Corp. Files Q1 2025 10-Q — 10-Q · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  Channel Therapeutics Corp. filed its 10-Q for the period ending March 31, 2025. The company, formerly Chromocell Therapeutics Corp, is incorporated in Nevada an
• Channel Therapeutics Files 8-K — 8-K · 2025-05-01T00:00:00.000Z [neutral] Risk: low
  Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) filed an 8-K on May 1, 2025, reporting on financial statements and exhibits. The company, in
• Channel Therapeutics Corp. Files 8-K with Material Agreements & Updates — 8-K · 2025-04-17T00:00:00.000Z [neutral] Risk: medium
  On April 17, 2025, Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) entered into a material definitive agreement. The company also reported o
• Channel Therapeutics Corp. Files 2024 10-K — 10-K · 2025-03-27T00:00:00.000Z [neutral] Risk: low
  Channel Therapeutics Corp. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company,
• Channel Therapeutics Corp. Enters Material Definitive Agreement — 8-K · 2025-03-03T00:00:00.000Z [neutral] Risk: medium
  On February 25, 2025, Channel Therapeutics Corp. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly kno
• Channel Therapeutics Corp. Files 8-K — 8-K · 2024-11-21T00:00:00.000Z [neutral] Risk: low
  On November 21, 2024, Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) filed an 8-K report. The filing indicates the company's principal exec
• Channel Therapeutics Corp. Files 8-K with Major Corporate Updates — 8-K · 2024-11-18T00:00:00.000Z [neutral] Risk: medium
  Channel Therapeutics Corp. announced on November 18, 2024, a material definitive agreement, the creation of a direct financial obligation, and modifications to
• Chromocell Therapeutics Files Q3 2024 10-Q — 10-Q · 2024-11-13T00:00:00.000Z [neutral] Risk: medium
  Chromocell Therapeutics Corp filed its 10-Q for the period ending September 30, 2024. The company, located at 685 US Highway One, North Brunswick, NJ, is involv
• Chromocell Therapeutics Corp Files 8-K — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  On October 22, 2024, Chromocell Therapeutics Corporation filed an 8-K report detailing a submission of matters to a vote of security holders, other events, and
• Chromocell Therapeutics Files Definitive Proxy Statement — DEF 14A · 2024-09-26T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp filed a Definitive Proxy Statement (DEF 14A) on September 26, 2024, for its annual meeting. The filing concerns the company's corpo
• Chromocell Therapeutics Files Q2 2024 10-Q — 10-Q · 2024-08-13T00:00:00.000Z [neutral] Risk: medium
  Chromocell Therapeutics Corp filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Specific financ
• Chromocell Therapeutics Files 8-K — 8-K · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corporation filed an 8-K on August 7, 2024, reporting an event that occurred on August 5, 2024. The filing is categorized under 'Other E
• Chromocell Therapeutics Reports Material Agreement and Financial Updates — 8-K · 2024-07-29T00:00:00.000Z [neutral] Risk: medium
  Chromocell Therapeutics Corporation entered into a material definitive agreement on July 24, 2024. The company also incurred a direct financial obligation or an
• Chromocell Therapeutics Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-15T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp (PTHS) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Chromocell Therapeutics Corp filed a 10-Q report for the perio
• Chromocell Therapeutics Corp. Files 2023 Annual Report on Form 10-K — 10-K · 2024-04-16T00:00:00.000Z [neutral] Risk: medium
  Chromocell Therapeutics Corp (PTHS) filed a Annual Report (10-K) with the SEC on April 16, 2024. Chromocell Therapeutics Corp. filed its annual report on Form 1
• Chromocell Therapeutics Files 8-K — 8-K · 2024-04-09T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corporation filed an 8-K on April 9, 2024, to report other events and financial statements. The filing details the company's principal e
• Chromocell Therapeutics Files 8-K — 8-K · 2024-03-21T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corporation filed an 8-K on March 21, 2024, reporting on its current activities. The filing includes information regarding financial sta
• Chromocell Therapeutics Moves HQ, Files Officer/Director Changes — 8-K · 2024-03-18T00:00:00.000Z [neutral] Risk: medium
  Chromocell Therapeutics Corp. announced on March 13, 2024, a change in its principal executive office to 4400 Route 9 South, Suite 1000, Freehold, NJ 07728. Thi
• Chromocell Therapeutics Files 8-K — 8-K · 2024-03-13T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp. filed an 8-K on March 13, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• SC 13G Filing — SC 13G · 2024-03-04T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-03-01T00:00:00.000Z [neutral]
• Ezra Friedberg Discloses Significant Stake in Chromocell Therapeutics — SC 13D · 2024-02-26T00:00:00.000Z [neutral] Risk: medium
  Ezra M. Friedberg filed an initial Schedule 13D on February 26, 2024, reporting beneficial ownership of Chromocell Therapeutics Corporation (CUSIP 171126105) co
• Chromocell Therapeutics Amends Bylaws, Sells Equity — 8-K · 2024-02-22T00:00:00.000Z [neutral] Risk: medium
  Chromocell Therapeutics Corp. entered into a Material Definitive Agreement on February 15, 2024, involving an unregistered sale of equity securities. This event
• Chromocell Therapeutics Corp. Files Amendment No. 13 to Form S-1 Registration Statement — S-1/A · 2024-02-14T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp (PTHS) filed a Amended IPO Registration (S-1/A) with the SEC on February 14, 2024. Chromocell Therapeutics Corporation filed Amendm
• Chromocell Therapeutics Corp. Files Amendment No. 12 to S-1 Registration Statement — S-1/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp (PTHS) filed a Amended IPO Registration (S-1/A) with the SEC on February 12, 2024. Chromocell Therapeutics Corporation filed an ame
• Chromocell Therapeutics Corp. Files Amendment 11 to S-1 Registration Statement — S-1/A · 2024-02-07T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp (PTHS) filed a Amended IPO Registration (S-1/A) with the SEC on February 7, 2024. Chromocell Therapeutics Corporation filed an amen
• Chromocell Therapeutics Corp. Files Amendment 10 to S-1 Registration Statement — S-1/A · 2024-01-30T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp (PTHS) filed a Amended IPO Registration (S-1/A) with the SEC on January 30, 2024. Chromocell Therapeutics Corporation filed Amendme
• Chromocell Therapeutics Corp. Files Amendment No. 9 to Form S-1 Registration Statement — S-1/A · 2024-01-16T00:00:00.000Z [neutral] Risk: low
  Chromocell Therapeutics Corp (PTHS) filed a Amended IPO Registration (S-1/A) with the SEC on January 16, 2024. Chromocell Therapeutics Corporation filed Amendme